PRNewsWire
22 Sept 2026, 06:00 UTC · 2h ago
Verdict
Headline leans bullish. We score ABBV +0.80 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
The European Commission approved RINVOQ for the treatment of children aged two years and older with active polyarticular juvenile idiopathic arthritis.
Newpress release dated Sep 22, 2026
So whatAccess to an estimated 126,000 children in Europe creates a new revenue stream starting in the next few quarters.
More positive than 62% of claims this week
Continue reading
5 related stories
More positive than 84% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
In the SELECT-YOUTH study, RINVOQ achieved a 79.5% ACR pediatric 70 response rate at week 48.
Newpress release dated Sep 22, 2026
So whatThe 13.1 percentage point improvement from week 12 to week 48 supports long-term patient retention and higher lifetime value per patient.
More positive than 43% of claims this week
The SELECT-YOUTH study reported 10.2 serious adverse events per 100 patient-years.
Newpress release dated Sep 22, 2026
So whatLow discontinuation rates (2.7 E/100 PY) suggest a favorable safety profile that minimizes the risk of restrictive black-box warnings in the EU.
More positive than 40% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
The company received European Commission approval for RINVOQ to treat children with active polyarticular juvenile idiopathic arthritis.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
2h ago
—
ABBV hasn't traded since this ran. Last close $264.53 (Sep 21); the reaction starts at the next open.
ABBV chart →